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Abstract
Background: Cluster of differentiation 69 (CD69), an early activation marker antigen on T and B cells, is also
expressed on activated macrophages and neutrophils, suggesting that CD69 may play a role in inflammatory
diseases. To determine the effect of CD69 deficiency on bleomycin(BLM)-induced lung injury, we evaluated the
inflammatory response following intratracheal BLM administration and the subsequent fibrotic changes in wild type
(WT) and CD69-deficient (CD69
-/-) mice.
Methods: The mice received a single dose of 3 mg/kg body weight of BLM and were sacrificed at 7 or 14 days
post-instillation (dpi). Lung inflammation in the acute phase (7 dpi) was investigated by differential cell counts and
cytokine array analyses of bronchoalveolar lavage fluid. In addition, lung fibrotic changes were evaluated at 14 dpi
by histopathology and collagen assays. We also used reverse transcription polymerase chain reaction to measure
the mRNA expression level of transforming growth factor b1 (TGF-b1) in the lungs of BLM-treated mice.
Results: CD69
-/- mice exhibited less lung damage than WT mice, as shown by reductions in the following indices:
(1) loss of body weight, (2) wet/dry ratio of lung, (3) cytokine levels in BALF, (4) histological evidence of lung injury,
(5) lung collagen deposition, and (6) TGF-b1 mRNA expression in the lung.
Conclusion: The present study clearly demonstrates that CD69 plays an important role in the progression of lung
injury induced by BLM.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial
pneumonia of unknown causes and has poor prognosis
[1,2]. Patients with IPF could be treated with steroids or
immunosuppressants to ameliorate the inflammation that
occurs early in the course of the disease, but these drugs
do not improve their survival [3]. Hence, the discovery of
a target that could be useful in the therapeutic interven-
tion of IPF is desirable.
Bleomycins (BLMs) are a family of glycopeptide anti-
biotics [4] with potent anti-tumor activity against a wide
range of lymphomas, head and neck cancers, and germ-
cell tumors [5]. However, the therapeutic efficacy of BLM
is limited by the development of pulmonary fibrosis in
patients using it [6,7]. BLM-induced pulmonary fibrosis
in mice is the most common experimental model of
human IPF. In this model, intratracheal administration of
BLM induces acute alveolitis and interstitial inflamma-
tion, which are characterized by the recruitment of leu-
kocytes within 1 week [8] and pulmonary edema.
Subsequently, during the second week, fibrotic responses,
such as fibroblast proliferation and synthesis of extracel-
lular matrix, occur [9]. Various types of cells, including
macrophages and neutrophils have been the immune
cells primarily implicated as playing potential roles in the
development of pulmonary fibrosis [10].
Cluster of differentiation 69 (CD69) is a C-type lectin
expressed as a disulfide-linked homodimeric membrane
protein [11]. The CD69 gene is located within the natural
killer (NK) gene complex on mouse chromosome 6 and
human chromosome 12 [12,13]. CD69 was initially
detected on the surface of activated lymphocytes and is
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However, CD69 expression is not restricted to these cells,
since activated macrophages, neutrophils, and eosino-
phils can also express CD69 [17-19]. Moreover, antibody
crosslinking of CD69 induces several cellular responses,
including nitric oxide (NO) production and release of
tumor necrosis factor a (TNF-a) in murine macrophages
[17], NO production in human monocytes [20], neutro-
phil degranulation [18], T cell proliferation and produc-
tion of TNF-a [21,22], and NK cell cytotoxicity [23].
These facts indicate that CD69 exerts a potential proin-
flammatory function and may be involved in the patho-
genesis of inflammatory diseases such as pulmonary
fibrosis. To determine the effects of CD69 deficiency on
BLM-induced lung injury, we evaluated the inflammatory
response to intratracheal BLM administration and the





Eight-week-old male C57BL/6J mice were purchased
from Clea Japan (Tokyo, Japan). CD69
-/- mice [24] were
backcrossed with C57BL/6J 10 times. Male CD69
-/- and
WT mice (8-10 weeks) were used in this study. All mice
used in this study were bred in the Animal Resource
Facility at Chiba University under pathogen-free condi-
tions and cared for according to the animal care guide-
lines of Chiba University.
Induction of lung injury by bleomycin
Prior to experimentation, mice were weighed and anaes-
thetized with an intraperitoneal injection of tribro-
moethanol. Subsequently, the animals were given a single
intratracheal injection of BLM hydrochloride (3 mg⋅kg
-1;
Nippon Kayaku, Tokyo, Japan) dissolved in phosphate-
buffered saline (PBS) by using a Microsprayer
® atomizer
(PennCentury, Philadelphia, PA). Control mice received a
sham treatment of PBS.
Measurement of fluid content in lung
The right lung was carefully excised, and then its wet
weight was measured. Subsequently, the lung was dried
for 24 h at 60°C, and then its dry weight was measured.
The ratio between wet and dry lung weight is a measure
of edema formation.
Collection of bronchoalveolar lavage fluid
Seven days after BLM administration, mice were anesthe-
tized with pentobarbital (Schering-Plough, Kenilworth,
NJ) and sacrificed. The trachea was exposed and lavaged
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The lavage fluids were pooled and then centrifuged at
300 × g for 5 min at 4°C. The resulting supernatants were
stored at -80°C for chemokine and cytokine measure-
ments. The pellets were resuspended in PBS to determine
the total and differential cell counts of the bronchoalveo-
lar lavage fluid (BALF). The total cell count was mea-
sured by using a hemocytometer. The differential cell
count was determined by manually counting 200 cells
per mouse that were stained with Diff-Quick (Sysmex
Corporation, Kobe, Japan) and fixed on glass slides.
Measurement of cytokine levels
The level of cytokines in the BALF was measured by a
RayBio mouse inflammation antibody array 1 (RayBio-
tech, Norcross, GA). This assay employs a qualitative
westernblot (WB) screening technique that can detect 80
cytokines. We precisely followed the manufacturer’sp r o -
tocol. Briefly, the membranes were placed in an 8-well
tissue culture tray and incubated with blocking buffer at
room temperature for 30 min. One milliliter of BALF
sample was added to each membrane and incubated for
2 h. After the samples were removed and washed, the
membranes were incubated with the biotin-conjugated
antibodies specific for cytokines overnight at 4°C. After
washing, the membranes were incubated with 1:1,000
diluted horseradish peroxidase-conjugated streptoavidin
for 2 h at room temperature. Next, the membranes were
incubated with chemiluminescent detection buffer,
wrapped in plastic wrap, and exposed to radiographic
film (Kodak X-Omat; Kodak; Rochester, NY) for 40 s.
The visualized signals on the developed film were quanti-
fied by an image-processing and analysis program (Fuji
Image Gauge software version 3.0; Fujifilm, Tokyo,
Japan).
Histological examination
Lung biopsies were taken at 14 dpi with BLM or PBS.
Lung tissues were inflated and fixed in 4% paraformalde-
hyde, embedded in paraffin, and cut into 8-μm-thick sec-
tions. Sections were subjected to hematoxylin and eosin
(H-E) or Masson trichrome stain (Sigma-Aldrich, St.
Louis) according to the manufacturer’si n s t r u c t i o n s .T h e
severity of the fibrosis was semi-quantitatively assessed
according to the method proposed by Ashcroft and cow-
orkers [25]. Briefly, the grade of lung fibrosis was scored
on a scale from 0 to 8 by examining random sections at
100 × magnification. The general scoring criteria were as
follows: grade 0, normal lung; grade 1, minimal fibrous
thickening of the alveolar or bronchiolar walls; grade 3,
moderate thickening of the walls without obvious
damage to lung architecture; grade 5, significant fibrosis
with obvious damage to lung structure and formation of
fibrous bands or small fibrous masses; grade 7, severe dis-
tortion of lung structure and large fibrous masses; grade
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score of each lung section was reported as the mean
score of at least 20 microscopic fields.
Collagen assay
Desiccated caudal lobes from the right lung 14 d after
BLM administration were homogenized with 0.1 mg/mL
pepsin (Wako chemicals, Osaka, Japan) in 0.5 mol/L
acetic acid and incubated for 24 h at 4°C while stirring
constantly. Subsequently, the samples were centrifuged
at 10000 × g for 5 min at 4°C. The total lung collagen
content of the supernatant was measured by using the
Sircol Collagen Assay kit (Biocolor, Belfast, Northern
Ireland).
Expression of TGF-ß1 in bleomycin-treated lung
Mice were sacrificed at 7 dpi, and the lung was dissected
out. The RNA of the lung was isolated using ISOGEN
(Wako chemicals) according to the manufacturer’s
instructions. Single-stranded cDNA was synthesized
from prepared RNA (1 μg) with Moloney murine leuke-
mia virus reverse transcriptase (Invitrogen, Carlsbad, CA)
using an oligo(dT) primer (Invitrogen) in a total volume
of 20 μL. The resultant cDNA sample (1 μL) was sub-
jected to PCR for the amplification of mouse TGFß-1
cDNA using specific primers (sense primer, 5’-CAA-
CAACGCCATCTATGAGA-3’; antisense primer, 5’-
TATTCCGTCTCCTTGGTTC-3’). As an internal con-
trol, mouse glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA was amplified using specific primers
(sense primer, 5’-GACCACAGTCCATGACATCACT’-3;
antisense primer, 5’-TCCACCACCCTGTTGCTGTAG-
3’). The settings of the thermal cycler were 30 cycles of
45 s at 94°C, 1 min at 52°C, and 1 min at 72°C for mouse
TGFß-1 and 25 cycles of 40 s at 94°C, 1 min at 60°C, and
1 min at 72°C for mouse GAPDH. The amplified pro-
ducts were separated on a 1.2% agarose gel and visualized
with ethidium bromide staining under UV radiation. Spe-
cific amplification of the expected sizes (mouse TGFß-1,
295 bp; mouse GAPDH, 452 bp) was observed.
Immunohistochemical analysis
The lung fixed in 4% paraformaldehyde/0.1M sodium
phosphate buffer (pH 7.4) was embedded in OCT
(SAKURA Finetek, Tokyo) and cut into 10-μm-thick sec-
tions, which were placed on poly-L lysine-coated slides.
The sections were subjected to double staining with ham-
ster anti-CD69 monoclonal antibody (Biolegend, San
Diego, CA) in combination with rabbit anti-Iba1 polyclo-
nal antibody (Wako chemicals, Tokyo) followed by a
reaction with Alexa Fluor 594-conjugated anti-hamster
antibody or Alexa Fluor 488-conjugated anti-rabbit anti-
body. The sections were simultaneously stained with 4’,6-
diamino-2-phenylindole (DAPI). To confirm the precise
localization of Iba1-positive cells, the sections were
stained with hamster anti-podoplanin/gp36 monoclonal
antibody, which detects alveolar epithelial cells and
thereby clearly visualizes the alveolar structure.
Statistical analysis
The Student’s t-test or analysis of variance (ANOVA)
with the Newman-Keuls test was used to determine
whether results were statistically significant (P < 0.05).
All statistical analyses were performed with GraphPad




To determine the biological significance of CD69 defi-
ciency after acute lung injury, we tracked weight
changes following BLM exposure. WT mice showed
typical and persistent body weight loss after BLM expo-
sure. In contrast, the CD69
-/- mice transiently lost body
weight after BLM exposure but underwent steady weight
gain thereafter. Between the two groups, a marked dif-
ference was observed (Figure 1). In mice injected with
PBS, the mice body showed daily weight gain without
any loss (data not shown).
Differential cell counts in bronchoalveolar lavage fluid
and lung edema
To determine whether the CD69 deficiency affected the
BLM-induced infiltration of inflammatory cells into the air-
ways and parenchyma, we differentially counted the
inflammatory cells in BALF at 7 dpi. As shown in Figure 2,
the numbers of total inflammatory cells, macrophages,
neutrophils, and lymphocytes in the BALF were signifi-
cantly elevated in the BLM-injected mice compared to
those in the PBS-injected mice (sham). Moreover, the
increase in these cell populations in the BLM-induced
Figure 1 Effect of bleomycin treatment on body weight in
wild-type and CD69-deficient mice. Time course of changes in
body weight after bleomycin (BLM) treatment in wild-type (WT) (n =
8) and cluster of differentiation 69 (CD69)-deficient (CD69
-/-) mice
(n = 6). Results are expressed as the mean (SEM), *P < 0.05.
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-/- mice.
Intratracheally BLM-treated mice showed an inflammatory
response characterized by the accumulation of water in the
lungs, indicative of tissue edema. CD69 deficiency signifi-
cantly reduced the lung fluid content resulting from BLM-
treatment (Figure 3).
Inflammatory cytokine levels in bronchoalveolar lavage
fluid
To evaluate whether CD69 deficiency affected the inflam-
matory responses induced by BLM, we comprehensively
investigated the differences in the expression of cytokines
involving chemokines in the BALF. As shown in Figure
4A, the expression of several cytokines and chemokines
in the BALF from WT and CD69
-/- mice was induced by
BLM. We focused on IL-6, MCP-1, TIMP-1, sTNF-R1,
sTNF-R2, and MIP-1g (Figure 4A & 4B). These cytokines
and chemokines were clearly induced by BLM in WT
mice but less so in CD69
-/- mice. Thus, the decreased
Figure 2 Effect of bleomycin treatment on differential cell counts in wild-type and CD69-deficient mice. Differential cell counts in
bronchoalveolar fluid (BALF) were determined 7 d after the instillation of BLM or phosphate-buffered saline (sham treatment). Results are
expressed as the mean (SEM) (n = 6-8 BLM-treated mice, n = 3 sham-treated mice). *P < 0.05, **P < 0.01.
Figure 3 Effect of bleomycin treatment on lung fluid content
in wild-type and CD69-deficient mice. Ratio of wet/dry lung
weight 7 d after the instillation of BLM or PBS (sham treatment).
Results are expressed as the mean (SEM) (n = 8 WT and 6 CD69
-/-
mice). The ratio between wet and dry lung weight is a measure of
edema formation. *P < 0.01 vs. sham-treated mice. †P < 0.01 vs. WT
mice.
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7 d after the instillation of BLM or PBS (sham treatment) in WT or CD69
-/- mice. Cytokines with increased expression levels are boxed. (B)
Expression levels of these cytokines in WT (black bars) and CD69
-/- (white bars) mice. Each expression level was normalized by that of the
positive control. The stimulation index is the ratio of the expression level of a cytokine in BLM-treated mice to that in sham-treated mice. Results
are expressed as the mean (SEM) (n = 4 mice per group). *P < 0.05, **P < 0.01.
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mechanisms underlying the attenuation of symptoms in
CD69
-/- mice, including the reduction in leukocytic infil-
tration and edema. An analysis by densitometer revealed
that the expression levels of these cytokines and chemo-
kines in BLM-treated CD69
-/- mice were significantly
lower than those in WT mice (Figure 4B).
Histological and biochemical changes in lung
For investigating the effects of CD69 deficiency on BLM-
induced lung fibrosis, the histopathological changes in the
lung were evaluated at 14 dpi. Representative microscopic
findings following H-E or Masson’s trichrome staining of
the lung sections are shown in Figure 5. The lung architec-
ture was nearly normal between the two genotypes
injected with PBS. However, the WT lung tissue exposed
to BLM showed a strong accumulation of inflammatory
cells, thickening of the alveolar walls, and fibrotic lesions.
Although these findings were also observed in the CD69
-/-
mice, the extent and intensity were much less than those
in the WT mice. The severity of the fibrosis was also
assessed by Ashcroft scoring. This assessment confirmed
that the severity of fibrosis was significantly reduced in
BLM-treated CD69
-/- mice relative to that in the
correspondingly injured WT mice (Figure 6A). In accor-
dance with the results of the Ashcroft scoring, collagen
deposition was markedly developed in the lungs of BLM-
treated WT mice at 14 dpi compared to that in the sham
group. Moreover, the increased collagen contents induced
by BLM were significantly attenuated in CD69
-/- mice
(Figure 6B). TGF-b1 mRNA expression in the lung tissue
was measured by RT-PCR at 7 dpi. The BLM-induced
expression of TGF-ß1 was strongly reduced in CD69
-/-
mice relative to that in WT mice (Figure 6C).
Predominant localization of CD69 in lung
As shown in Figure 7A, Iba1-positive macrophages were
o b s e r v e di nt h el u n g sf r o mW TP B S - i n j e c t e dm i c eb u t
rarely exhibited CD69-like immunoreactivity. On the
other hand, Iba1
+/CD69
+ macrophages were clearly
observed in the lung from WT BLM-treated mice at 2
dpi (Figure 7B), indicating that the expression of CD69
was induced in the macrophages exposed to BLM. In
addition, Iba1 recognized alveolar and interstitial macro-
phages, suggesting that BLM induced CD69 expression
in the two types of macrophages (Figure 7C). At 2 dpi
after BLM injection, T cells and neutrophils were barely
detected as infiltrating cells in the lung (data not shown).
Figure 5 Effect of bleomycin on the lung architecture in wild-type and CD69-deficient mice. Comparison of the lung architecture in WT
and CD69
-/- mice after instillation of BLM or PBS (sham treatment), as shown by hematoxylin-eosin (A) and Masson’s trichrome (B) staining of
representative tissue sections.
Yamauchi et al. Respiratory Research 2011, 12:131
http://respiratory-research.com/content/12/1/131
Page 6 of 10Discussion
The ability of CD69 to function as a signal transducing
molecule in various types of cells, together with its upre-
gulation in certain inflammatory diseases, suggests a
possible pathogenic role for CD69 [26]. Indeed, CD69 is
persistently expressed in the infiltrates of leukocytes
produced during the course of chronic inflammatory
diseases such as chronic hepatitis [27] and rheumatoid
arthritis [28]. Recently, Miki et al. demonstrated that
CD69 expressed on CD4-positive T cells plays a critical
role in the development of allergen-induced eosinophilic
inflammation [29]. These findings led us to consider
that the gene disruption of CD69 could affect the patho-
genesis of pulmonary inflammatory diseases. To address
to this notion, we investigated the development of
BLM-induced lung injury in CD69
-/- mice.
The importance of a profibrotic inflammatory process
in the pathogenesis of pulmonary fibrosis has been sug-
gested in a number of studies that have found that lung
injury leads to an inflammatory reaction characterized by
the production of inflammatory cytokines and the
recruitment of leukocytes [30]. In this study, we showed
that inflammatory responses such as an accumulation of
inflammatory cells in the BALF and lung edema occur
after instillation with BLM. These parameters were sig-
nificantly reduced in CD69
-/- mice compared with WT
mice (Figures 2 & 3). The differences in the inflammatory
parameters between the CD69
-/- and WT mice were con-
sistent with the differences in the body weight profiles
reflecting a pathological state in the mice (Figure 1).
These results suggest that CD69
-/- mice are more resis-
tant to BLM-induced lung inflammation than WT ones.
This conclusion was supported by the WB array analysis
for cytokines/chemokines. The expression of BLM-
induced cytokines/chemokines (e.g., MCP-1, IL-6, TIMP-
1) in the WT mice was significantly reduced in CD69
-/-
mice (Figure 4). Likewise, these cytokines/chemokines
have been reported to play an important role in the
pathogenesis of pulmonary fibrosis [31-34]. Thus, the
reduced expression of these cytokines/chemokines
appears to be at least partly responsible for the suppres-
sion of the BLM-induced lung inflammation that leads to
fibrosis in CD69
-/- mice.
TGF-b1 plays a critical role in the pathogenesis of lung
fibrosis through the stimulation of collagen and fibronec-
tin production in fibroblasts [35]. Likewise, it is well
established that the initial elevation of pro-inflammatory
cytokines leads to an increase in the expression of pro-
fibrotic markers involving TGF-b1. This increased
expression appears to occur in the following manner: 1)
MCP-1 may act as a profibrotic mediator by promoting
fibroblast procollagen gene expression through the up-
regulation of TGF-b1 [36]; and 2) TNF signaling through
sTNF-receptors contributes to the regulation of TGF-b1
expression during BLM-induced lung fibrosis, as mice
lacking sTNF-receptors have been shown to be resistant
to BLM-induced lung fibrosis [30]. These facts strongly
suggest the possibility that the expression of cytokines/
chemokines involving MCP-1 and sTNF-receptors in the
lung can affect the extent of TGF-b1 expression and the
fibrotic tissue profiles. As expected, BLM-induced
expression of TGF-b1 mRNA prior to fibrosis was sup-
pressed in the lungs of CD69
-/- mice relative to that in
WT mice (Figure 6C). Furthermore, lung fibrosis was
markedly attenuated in the CD69
-/- mice (Figures. 5, 6A
& 6B).
By immunohistochemical analysis, CD69 was predomi-
nantly expressed in macrophages after BLM administration
Figure 6 Effect of bleomycin on lung fibrotic and biochemical
changes in wild-type and CD69-deficient mice.( A) Ashcroft
scores, which are a semi-quantitative measure of lung fibrotic
changes, were determined 14 d after the instillation of BLM or PBS
(sham treatment). Please see the Methods section for an explanation
of the scoring criteria. Results are expressed as the mean (SEM) (n =4
mice per group). *P < 0.01 vs. sham-treated mice. †P < 0.01 vs. WT
mice. (B) The lung collagen content was measured 14 d after the
instillation of BLM or PBS (sham treatment). Results are expressed as
mean (SEM) (n = 6-8 BLM-treated mice, n = 3 sham-treated mice). *P
< 0.01 vs. sham-treated mice. †P < 0.01 vs. WT mice. (C) The mRNA
expression level of TGF-b1 in the lung was measured 7 d after the
instillation of BLM or PBS in WT or CD69KO mice.
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point, the infiltration of T cells and neutrophils was not
observed. These results suggest that CD69 on macrophages
may play an important role in the initial step of BLM-
induced lung injury. Macrophages are thought to play a
pivotal role in the pathogenesis of pulmonary fibrosis. Acti-
vated macrophages secrete a variety of enzymes, comple-
ment components, cytokines, and other mediators of
inflammatory and fibroblast cell function [37]. It has been
also reported for in vitro and in vivo studies that alveolar
macrophages release proinflammatory cytokines after BLM
administration [38]. Furthermore, it is thought that alveolar
macrophages, following stimulation by BLM-induced
injury, secrete a large quantity of TGF-b1a n dt h e r e b y
induce the lung fibroblasts in the alveolar interstitium to
synthesize collagen, resulting in pulmonary fibrosis [39,40].
These suggest that BLM-activated macrophages may func-
tion as one of major sources of chemical mediators in the
pulmonary inflammation/fibrosis loop. Indeed, the majority
of inflammatory cells recovered by BAL were macrophages,
which were of an order of magnitude higher in number
than those of neutrophils and lymphocytes (Figure 2).
An important question is the role of CD69 on macro-
phages in the induction of IPF. Previous studies have
reported the ability of the CD69 antigen to act as a
potent trigger of murine macrophage activation [17].
The stimulation of macrophages with anti-CD69 mAb
has been shown to induce both NO production and
TNF-a release. Likewise, it has been found that CD69
cross-linking induces TGF-b1 production in macro-
phages as well as in T cells and NK cells [41,42]. We
also confirmed a clear difference between macrophages
from WT mice and those from CD69
-/- mice in the
secretion of LPS-induced cytokines/chemokines (unpub-
lished data). Hence, it is indisputable that CD69 can
participate in the activation and regulation of macro-
phages in the inflammatory process. Although the sig-
naling loop of CD69/TGF-b in activated macrophages
may contribute to IPF in a direct manner, it is of inter-
est as to whether BLM-associated tissue injury induces
the expression of the putative CD69 ligand on certain
cells, such as epithelial cells, especially from the stand-
point of epithelial mesenchymal transition (EMT).
Further study will be necessary to determine the precise
molecular mechanisms of CD69-mediated development
in IPF.
Conclusion
We have shown for the first time that CD69 plays a key
role in promoting inflammation and fibrosis in the
BLM-injured lung. The present study suggests that
CD69 may be a potentially useful target in the therapeu-
tic intervention of IPF.
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